Gain Therapeutics (NASDAQ:GANX) Given "Buy" Rating at HC Wainwright

Key Points

• Gain Therapeutics' stock has been given a "buy" rating by HC Wainwright, with a target price of $8.00, indicating a potential upside of306.09% from its previous close.
• Investment analysts have offered varying ratings and price targets, but seven analysts rate it as a "Buy", while one has given it a "Sell" rating.
• The company's shares opened at $1.97, with a market capitalization of $70.82 million, while it has a 12-month low of $1.41 and high of $3.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright's target price would indicate a potential upside of 306.09% from the stock's previous close.

GANX has been the subject of a number of other reports. Roth Capital lowered their price objective on shares of Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Maxim Group upped their price objective on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Tuesday, October 7th. BTIG Research reiterated a "buy" rating and set a $9.00 target price on shares of Gain Therapeutics in a research report on Monday, September 8th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Gain Therapeutics in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Gain Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $7.86.

Gain Therapeutics Price Performance

Shares of NASDAQ:GANX opened at $1.97 on Monday. The firm has a 50 day moving average of $1.76 and a 200-day moving average of $1.78. The stock has a market capitalization of $70.82 million, a PE ratio of -3.13 and a beta of 0.11. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.09. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $3.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, equities research analysts predict that Gain Therapeutics will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

Several institutional investors have recently added to or reduced their stakes in GANX. Dauntless Investment Group LLC bought a new position in Gain Therapeutics during the first quarter valued at about $240,000. Marshall Wace LLP grew its position in Gain Therapeutics by 41.0% during the second quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock valued at $498,000 after buying an additional 80,407 shares during the period. Kovitz Investment Group Partners LLC bought a new position in Gain Therapeutics during the first quarter valued at about $91,000. Finally, Geode Capital Management LLC grew its position in Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock valued at $523,000 after buying an additional 8,251 shares during the period. Institutional investors own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.